Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001193125-26-458471
What the release said
On November 12, 2026, Atrium Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2026.
Atrium reported collaboration revenue of $15.3 million for the third quarter of 2026, primarily from a $15.0 million BMS milestone, with R&D expenses of $13.8 million and G&A expenses of $8.2 million.¶2¶3¶4
Atrium closed a $50 million private placement with leading institutional investors in October 2026, and pro-forma cash was $293.6 million as of September 30, 2026, expected to fund operations through 2028.¶5¶6
Atrium dosed the first patient in the Corventis Phase 1/2 trial of ATR 1072 in PRKAG2 syndrome and expects initial proof of concept data in the second half of 2027.¶7
- Collaboration revenue, third quarter 2026
- $15.3 million¶2
- Research and development expenses, third quarter 2026
- $13.8 million¶3
- General and administrative expenses, third quarter 2026
- $8.2 million¶4
- Private placement
- $50 million¶5
- Cash, cash equivalents and short-term investments
- $232.1 million As of September 30, 2026, before the BMS milestone and private placement proceeds¶6
- Pro-forma cash balance
- $293.6 million As of September 30, 2026, including the BMS milestone and net private placement proceeds; expected to fund operations through 2028¶6
Same quarter
| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | $15.32M | $12.34M |
| Net Income | -$4.27M | -$37.00K |
| EPS Diluted | -$0.25 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Atrium Therapeutics, Inc. · CIK 2093101 · Engraved from SEC EDGAR